US · AMRX
Amneal Pharmaceuticals, Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Bridgewater, NJ 08807
- Website
- amneal.com
Price · as of 2025-12-31
$12.83
Market cap 4.34B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $38.76 | +202.1% |
| Intrinsic Value(DCF) | $10.30 | -19.72% |
| Graham-Dodd Method(GD) | $2.08 | -83.77% |
| Graham Formula(GF) | $3.63 | -71.71% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | $0.00 | $27.39 | |||
| 2017 | $0.00 | $14.10 | |||
| 2018 | $11.91 | $27.32 | $399.98 | $0.00 | $0.00 |
| 2019 | $3.46 | $22.60 | $0.00 | $0.00 | $0.00 |
| 2020 | $6.02 | $86.05 | $49.18 | $1.58 | $18.15 |
| 2021 | $4.12 | $29.43 | $0.00 | $0.00 | $0.92 |
| 2022 | $1.53 | $32.44 | $0.00 | $0.00 | $0.00 |
| 2023 | $5.39 | $21.20 | $0.00 | $0.00 | $0.00 |
| 2024 | $8.90 | $28.41 | $0.02 | $0.00 | $0.00 |
| 2025 | $13.77 | $38.76 | $3.57 | $2.08 | $3.63 |
AI valuation
Our deep-learning model estimates Amneal Pharmaceuticals, Inc.'s (AMRX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $38.76
- Current price
- $12.83
- AI upside
- +202.1%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$10.30
-19.72% upside
Graham-Dodd
$2.08
-83.77% upside
Graham Formula
$3.63
-71.71% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| AMRX | Amneal Pharmaceuticals, I… | $12.83 | 4.34B | +202% | -20% | -84% | -72% | 59.88 | 4.86 | 1.43 | -793.31 | — | -15.90 | 36.88% | 14.02% | 2.39% | 18.52% | 25.08% | 2.01% | 0.14 | 1.75 | 2.17 | 1.34 | 30.17 | -15789.00% | 805.00% | 2263.00% | 6.26% | 0.39 | 17.41% | 0.00% | 0.00% | 61.20% | 9.83 | 15.40 | 1.38 | 2.26 |
| BHC | Bausch Health Companies I… | $5.93 | 2.2B | +958% | +67% | — | +6% | 18.37 | -3.99 | 0.21 | 7.14 | — | -0.13 | 68.33% | 20.07% | 1.51% | -13.10% | 4.28% | 0.45% | -38.35 | 1.37 | 1.47 | 0.88 | 6.42 | -41538.00% | 711.00% | -2040.00% | 45.49% | 0.34 | 5.18% | 0.00% | 0.00% | 34.48% | 10.68 | 22.02 | 2.14 | 0.28 |
| DYN | Dyne Therapeutics, Inc. | $15.62 | 2.57B | — | — | — | — | -3.68 | 1.85 | — | -1.74 | — | 1.85 | 0.00% | — | — | -88.03% | -9599.05% | -74.14% | 0.04 | — | 15.60 | 15.20 | 1.31 | -1468.00% | — | 5604.00% | -25.25% | -6.92 | -8227.36% | 0.00% | 0.00% | 27.18% | -1.60 | -1.86 | — | 8.91 |
| INDV | Indivior Pharmaceuticals … | $32.72 | 4.08B | +249% | +42% | -77% | -38% | 19.04 | -40.38 | 3.23 | 12.71 | 0.18 | -39.58 | 80.23% | 21.15% | 16.95% | -93.96% | -87.53% | 16.67% | -0.62 | 5.82 | 0.71 | 0.49 | -0.44 | 1083333.00% | 429.00% | -142857.00% | -2.33% | -0.03 | 35.36% | 0.00% | 0.00% | 5.03% | 14.75 | -41.54 | 3.12 | 3.05 |
| LNTH | Lantheus Holdings, Inc. | $74.91 | 5.09B | +40% | +25% | -60% | -60% | 22.05 | 4.73 | 3.34 | 14.36 | — | 40.39 | 61.10% | 20.16% | 15.15% | 21.45% | 30.32% | 11.10% | 0.00 | 15.74 | 2.70 | 2.15 | -1.07 | -2179.00% | 50.00% | -2820.00% | 6.88% | 1.17 | 46.40% | 0.00% | 0.00% | 1.26% | 15.41 | 13.53 | 3.11 | 4.60 |
| MIRM | Mirum Pharmaceuticals, In… | $92.29 | 4.77B | -16% | +4,973% | -96% | — | -193.57 | 14.37 | 8.67 | 259.00 | — | 84.11 | 80.71% | -4.25% | -4.48% | -8.65% | -8.65% | -3.09% | 1.01 | -1.54 | 2.67 | 2.46 | 1.20 | -7459.00% | 5474.00% | 48801.00% | 1.21% | 0.27 | 21.44% | 0.00% | 0.00% | 1.65% | -201.32 | 81.21 | 8.55 | 5.05 |
| NVST | Envista Holdings Corp | $29.21 | 4.8B | +59% | -47% | -80% | -85% | 105.23 | 1.59 | 1.82 | 15.93 | — | 40.91 | 55.02% | 8.30% | 1.73% | 1.56% | 2.57% | 0.85% | 0.55 | 6.17 | 2.38 | 1.93 | 1.45 | -10431.00% | 832.00% | -2389.00% | 4.66% | 0.32 | 6.57% | 0.00% | 0.00% | 3.37% | 24.11 | 23.62 | 2.00 | 1.90 |
| PRGO | Perrigo Company plc | $13.22 | 1.82B | -63% | -63% | — | — | -1.20 | 0.58 | 0.40 | -1.52 | -0.17 | 1.94 | 35.14% | 8.07% | -33.51% | -39.29% | 6.99% | -15.68% | 0.01 | 2.11 | 2.76 | 1.13 | 0.62 | 72320.00% | -275.00% | -4068.00% | 8.49% | 0.24 | 2.96% | 9.32% | -11.20% | 217.29% | 3.54 | 8.37 | 0.29 | 0.46 |
| SLNO | Soleno Therapeutics, Inc. | $39.07 | 2.1B | — | -51% | -73% | — | 99.43 | 4.61 | 10.91 | 62.51 | — | 4.66 | 98.58% | 7.85% | 10.97% | 6.01% | 19.44% | 4.67% | 0.01 | 2.73 | 5.80 | 5.44 | -2.38 | -10890.00% | — | -16741.00% | 2.25% | 0.76 | 60.75% | 0.00% | 0.00% | 6.38% | 118.68 | 37.97 | 9.32 | 10.94 |
| SUPN | Supernus Pharmaceuticals,… | $54.73 | 3.14B | +101% | -41% | -57% | -59% | 23.92 | 1.71 | 2.67 | 7.56 | 0.44 | 4.45 | 88.23% | 12.34% | 11.16% | 7.55% | 9.31% | 5.58% | 0.03 | — | 2.35 | 2.04 | -0.20 | 546962.00% | 894.00% | 5491.00% | 9.69% | 0.59 | 25.85% | 0.00% | 0.00% | 0.09% | 16.50 | 7.87 | 2.04 | 4.79 |
| TLX | Telix Pharmaceuticals Lim… | $7.25 | 2.43B | +233% | +1,741% | -93% | — | -340.42 | 5.85 | 3.02 | 52.73 | — | -13.68 | 53.11% | 2.21% | -0.89% | -1.80% | 3.26% | -0.65% | 1.26 | 0.48 | 1.43 | 1.21 | 7.16 | -12257.00% | 5391.00% | -38842.00% | -2.28% | -0.07 | -10.14% | 0.00% | 0.00% | 0.00% | 158.00 | -50.84 | 3.49 | 2.55 |
About Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
- CEO
- Chirag K. Patel
- Employees
- 8.3K
- Beta
- 1.35
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($10.30 ÷ $12.83) − 1 = -19.72% (DCF, example).